Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.

Today, the American Cancer Society (ACS) released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. According to the study, prostate ...

Following almost a decade of decline, prostate cancer incidence in the U.S. increased 3.0% per year between 2014 through 2021, according to a report published Sept. 2 in CA: A Cancer Journal for ...

A sustained reduction in deaths from prostate cancer was observed with prostate-specific antigen (PSA) testing in long-term follow-up results from the European Randomized Study of Screening for ...

Prostate cancer rates have risen in recent years, with a sharp increase in cases diagnosed in advanced stages, the American Cancer Society said Tuesday. Diagnoses of prostate cancer rose 3% annually ...

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society. In the US, advanced prostate cancer diagnoses ...

Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...

The rate of people dying from cancer in the United States continued to decline for the 26th year in a row, according to a new American Cancer Society report. From 2016 to 2017, the United States saw ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...

Sept. 16 -- TUESDAY, Sept. 15 (HealthDay News) -- Older men diagnosed with prostate cancer who choose watchful waiting are doing better these days than in the era before screening with a test for ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...